Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.
Covino DA, Purificato C, Catapano L, Galluzzo CM, Gauzzi MC, Vella S, Lefebvre E, Seyedkazemi S, Andreotti M, Fantuzzi L. Covino DA, et al. Among authors: seyedkazemi s. Front Immunol. 2018 Aug 8;9:1839. doi: 10.3389/fimmu.2018.01839. eCollection 2018. Front Immunol. 2018. PMID: 30135687 Free PMC article.
Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism.
DʼAntoni ML, Paul RH, Mitchell BI, Kohorn L, Fischer L, Lefebvre E, Seyedkazemi S, Nakamoto BK, Walker M, Kallianpur KJ, Ogata-Arakaki D, Ndhlovu LC, Shikuma C. DʼAntoni ML, et al. Among authors: seyedkazemi s. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):108-116. doi: 10.1097/QAI.0000000000001752. J Acquir Immune Defic Syndr. 2018. PMID: 29781885 Free PMC article. Clinical Trial.
Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment.
Alagaratnam J, Dilly-Penchala S, Challenger E, Else L, Legg K, Petersen C, Jones B, Kulasegaram R, Seyedkazemi S, Lefebvre E, Khoo S, Winston A. Alagaratnam J, et al. Among authors: seyedkazemi s. Br J Clin Pharmacol. 2019 May;85(5):1039-1040. doi: 10.1111/bcp.13878. Epub 2019 Mar 4. Br J Clin Pharmacol. 2019. PMID: 30834549 Free PMC article. No abstract available.
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, Francque S, Farrell G, Kowdley KV, Craxi A, Simon K, Fischer L, Melchor-Khan L, Vest J, Wiens BL, Vig P, Seyedkazemi S, Goodman Z, Wong VW, Loomba R, Tacke F, Sanyal A, Lefebvre E. Friedman SL, et al. Among authors: seyedkazemi s. Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan 29. Hepatology. 2018. PMID: 28833331 Free PMC article. Clinical Trial.
Chronic alcohol-induced neuroinflammation involves CCR2/5-dependent peripheral macrophage infiltration and microglia alterations.
Lowe PP, Morel C, Ambade A, Iracheta-Vellve A, Kwiatkowski E, Satishchandran A, Furi I, Cho Y, Gyongyosi B, Catalano D, Lefebvre E, Fischer L, Seyedkazemi S, Schafer DP, Szabo G. Lowe PP, et al. Among authors: seyedkazemi s. J Neuroinflammation. 2020 Oct 9;17(1):296. doi: 10.1186/s12974-020-01972-5. J Neuroinflammation. 2020. PMID: 33036616 Free PMC article.
Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
Nielsen MJ, Leeming DJ, Goodman Z, Friedman S, Frederiksen P, Rasmussen DGK, Vig P, Seyedkazemi S, Fischer L, Torstenson R, Karsdal MA, Lefebvre E, Sanyal AJ, Ratziu V. Nielsen MJ, et al. Among authors: seyedkazemi s. J Hepatol. 2021 Dec;75(6):1292-1300. doi: 10.1016/j.jhep.2021.08.016. Epub 2021 Aug 27. J Hepatol. 2021. PMID: 34454994 Free article.
Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.
Anstee QM, Neuschwander-Tetri BA, Wong VW, Abdelmalek MF, Younossi ZM, Yuan J, Pecoraro ML, Seyedkazemi S, Fischer L, Bedossa P, Goodman Z, Alkhouri N, Tacke F, Sanyal A. Anstee QM, et al. Among authors: seyedkazemi s. Contemp Clin Trials. 2020 Feb;89:105922. doi: 10.1016/j.cct.2019.105922. Epub 2019 Dec 24. Contemp Clin Trials. 2020. PMID: 31881392 Free article.
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM. Pedrosa M, et al. Among authors: seyedkazemi s. Contemp Clin Trials. 2020 Jan;88:105889. doi: 10.1016/j.cct.2019.105889. Epub 2019 Nov 13. Contemp Clin Trials. 2020. PMID: 31731005
Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.
Vos MB, Dimick-Santos L, Mehta R, Omokaro SO, Taminiau J, Schabel E, Kleiner DE, Szitanyi P, Socha P, Schwimmer JB, Noviello S, Silberg DG, Torstenson R, Miller V, Lavine JE; Liver Forum Pediatric Working Group. Vos MB, et al. Gastroenterology. 2019 Dec;157(6):1448-1456.e1. doi: 10.1053/j.gastro.2019.08.048. Epub 2019 Sep 12. Gastroenterology. 2019. PMID: 31520612 Free PMC article. No abstract available.
17 results